Axonics’ Q3 2024: Revenue Growth Amid Challenges
Company Announcements

Axonics’ Q3 2024: Revenue Growth Amid Challenges

Axonics Modulation Technologies ( (AXNX) ) has released its Q3 earnings. Here is a breakdown of the information Axonics Modulation Technologies presented to its investors.

Axonics, Inc. is a medical technology company that develops and commercializes innovative products aimed at treating bladder and bowel dysfunction, primarily operating in the healthcare sector with a focus on minimally invasive solutions.

In its latest earnings report for the third quarter of 2024, Axonics reported a robust revenue growth of 25% year-over-year, driven by increased utilization of its sacral neuromodulation and Bulkamid products. Despite this growth, the company faced a slight net loss primarily due to one-time legal and acquisition-related costs.

The financial highlights include a net revenue of $116.2 million, with sacral neuromodulation and Bulkamid revenues both experiencing a 25% increase compared to the previous year. The gross margin improved to 77.2% from 74.2%, while the adjusted EBITDA rose significantly to $23.6 million from $14.0 million in the prior year period. However, the company reported a loss from operations of $6.3 million, influenced by $8 million in one-time expenses.

Looking ahead, Axonics remains committed to expanding its market presence and delivering life-changing therapies for incontinence. The management anticipates a positive trajectory as the company progresses towards its strategic goals and continues to innovate in its field.

Related Articles
TheFlyAxonics reports Q3 EPS 0c, consensus 13c
Howard KimAXNX Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App